KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.96

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.

S Novello, V Torri, C Grohe, S Kurz, M Serke, T Wehler, A Meyer, D Ladage, M Geissler, I Colantonio, C Cauchi, E Stoelben, A Ceribelli, C Kropf-Sanchen, G Valmadre, G Borra, M Schena, A Morabito, A Santo, V Gregorc, R Chiari, M Reck, G Schmid-Bindert, G Folprecht, F Griesinger, A Follador, P Pedrazzoli, A Bearz, O Caffo, N J Dickgreber, L Irtelli, G Wiest, V Monica, L Porcu, C Manegold, G V Scagliotti

Ann Oncol 33(1) 57-66

PMID34624497
PMCID-
DOI10.1016/j.annonc.2021.09.017
发表日期2021-10-08
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
摘要

摘要

BACKGROUND: Several strategies have been investigated to improve the 4% survival advantage of adjuvant chemotherapy in early-stage non-small-cell lung cancer (NSCLC). In this investigator-initiated study we aimed to evaluate the predictive utility of the messenger RNA (mRNA) expression levels of excision repair cross complementation group 1 (ERCC1) and thymidylate synthase (TS) as assessed in resected tumor. PATIENTS AND METHODS: Seven hundred and seventy-three completely resected stage II-III NSCLC patients were enrolled and randomly assigned in each of the four genomic subgroups to investigator's choice of platinum-based chemotherapy (C, n = 389) or tailored chemotherapy (T, n = 384). All anticancer drugs were administered according to standard doses and schedules. Stratification factors included stage and smoking status. The primary endpoint of the study was overall survival (OS). RESULTS: Six hundred and ninety patients were included in the primary analysis. At a median follow-up of 45.9 months, 85 (24.6%) and 70 (20.3%) patients died in arms C and T, respectively. Five-year survival for patients in arms C and T was of 65.4% (95% CI (confidence interval): 58.5% to 71.4%) and 72.9% (95% CI: 66.5% to 78.3%), respectively. The estimated hazard ratio (HR) was 0.77 (95% CI: 0.56-1.06, P value: 0.109) for arm T versus arm C. HR for recurrence-free survival was 0.89 (95% CI: 0.69-1.14, P value: 0.341) for arm T versus arm C. Grade 3-5 toxicities were more frequently reported in arm C than in arm T. CONCLUSION: In completely resected stage II-III NSCLC tailoring adjuvant chemotherapy conferred a non-statistically significant trend for OS favoring the T arm. In terms of safety, the T arm was associated with better efficacy/toxicity ratio related to the different therapeutic choices in the experimental arm.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。